Pyxis Oncology (NASDAQ:PYXS - Get Free Report) released its earnings results on Tuesday. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.01, Zacks reports. The firm had revenue of $16.15 million during the quarter.
Pyxis Oncology Trading Up 8.0 %
PYXS traded up $0.09 during midday trading on Friday, hitting $1.21. 912,320 shares of the company were exchanged, compared to its average volume of 745,908. The company's 50 day simple moving average is $1.33 and its 200 day simple moving average is $2.36. The firm has a market capitalization of $74.52 million, a price-to-earnings ratio of -1.17 and a beta of 1.11. Pyxis Oncology has a 1-year low of $0.99 and a 1-year high of $6.18.
Analysts Set New Price Targets
Several equities analysts recently issued reports on PYXS shares. HC Wainwright reissued a "buy" rating and issued a $5.00 target price on shares of Pyxis Oncology in a research report on Wednesday. Royal Bank of Canada reaffirmed an "outperform" rating and set a $8.00 price target on shares of Pyxis Oncology in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $9.20.
View Our Latest Research Report on Pyxis Oncology
Institutional Investors Weigh In On Pyxis Oncology
An institutional investor recently raised its position in Pyxis Oncology stock. Bank of America Corp DE increased its holdings in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) by 20.3% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 53,745 shares of the company's stock after acquiring an additional 9,062 shares during the period. Bank of America Corp DE owned approximately 0.09% of Pyxis Oncology worth $84,000 as of its most recent SEC filing. 39.09% of the stock is currently owned by hedge funds and other institutional investors.
Pyxis Oncology Company Profile
(
Get Free Report)
Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Featured Stories
Before you consider Pyxis Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pyxis Oncology wasn't on the list.
While Pyxis Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
